News

This section will highlight public scientific, financial and partnership disclosures. Citryll presents at conferences and aims towards publishing in peer-reviewed scientific journals.

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

We warmly welcome Paul Peter and Eric and are incredibly honoured to have them on the Board of Citryll. Their impressive and complementary track records in drug discovery and development in pharma, biotech and academia will add significant value…

Read More

Citryll completes € 18.5 M fundraise to develop CIT-013, an antibody targeting Neutrophil Extracellular Traps

Citryll announced it closed a total fundraise of € 18.5 million, led by Seventure (including their Health for Life Capital II fund), co-led by BioGeneration Ventures (BGV) with existing investors BOM Brabant Ventures, BrightGene and ModiQuest contributing…

Read More

Antibodies clamp down on NET nucleosomes

In the current issue of CMI, Chirivi et al. describe the isolation and characterization of a monoclonal antibody that may find applications in numerous inflammatory conditions. This new antibody, called tACPA, inhibits the completion …

Read More

Landmark paper on Citryll’s NET inhibitor programme published in Nature’s Cellular and Molecular Immunology

Oss, The Netherlands, March 20, 2020 —www.citryll.com Citryll announced today that a landmark scientific paper has been published in Nature’s Cellular and Molecular Immunology journal, to be found at …

Read More

Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases

Excessive release of neutrophil extracellular traps (NETs) is associated with disease severity and contributes to tissue injury, followed
by severe organ damage …

Read More

Citryll moves to new premises at Pivot Park in Oss, The Netherlands

Oss, The Netherlands, October 21, 2019 —www.citryll.com Citryll announced today that it
has occupied new office and lab space at the Pivot Park in Oss the Netherlands.

Read More

Citryll collaborates with leading NET researcher Dr. Markus Hoffmann

Oss, The Netherlands, Erlangen, Germany September 18, 2019 —http://www.citryll.com/ announced today that it has established a collaboration with Dr. Markus Hoffmann of the Department of Medicine 3, Friedrich Alexander University of …

Read More

Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013

Oss, The Netherlands and Basel, Switzerland, 9 September 2019 – The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013.

Read More